Literature DB >> 12459331

Production of clinical-grade recombinant adeno-associated virus vectors.

Richard O Snyder1, Terence R Flotte.   

Abstract

Recombinant adeno-associated viral (rAAV) vectors are being evaluated in animal models and humans. Pre-clinical data demonstrating vector safety, efficiency and efficacy have been used to initiate human clinical trials. The clinical manufacture of rAAV vectors has supported phase I and phase II trials, showing that adeno-associated virus serotype 2 vectors are safe when administered to humans.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12459331     DOI： 10.1016/s0958-1669(02)00369-5

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN： 0958-1669            Impact factor:   9.740


  18 in total

Review 1.  Cell cycle regulation to repair the infarcted myocardium.

Authors:  Joshua D Dowell; Loren J Field; Kishore B S Pasumarthi
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

2.  Stability and compatibility of recombinant adeno-associated virus under conditions commonly encountered in human gene therapy trials.

Authors:  Alisha M Gruntman; Lin Su; Qin Su; Guangping Gao; Christian Mueller; Terence R Flotte
Journal:  Hum Gene Ther Methods       Date:  2015-04       Impact factor: 2.396

3.  Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Authors:  Martin Lock; Susan McGorray; Alberto Auricchio; Eduard Ayuso; E Jeffrey Beecham; Véronique Blouin-Tavel; Fatima Bosch; Mahuya Bose; Barry J Byrne; Tina Caton; John A Chiorini; Abdelwahed Chtarto; K Reed Clark; Thomas Conlon; Christophe Darmon; Monica Doria; Anne Douar; Terence R Flotte; Joyce D Francis; Achille Francois; Mauro Giacca; Michael T Korn; Irina Korytov; Xavier Leon; Barbara Leuchs; Gabriele Lux; Catherine Melas; Hiroaki Mizukami; Philippe Moullier; Marcus Müller; Keiya Ozawa; Tina Philipsberg; Karine Poulard; Christina Raupp; Christel Rivière; Sigrid D Roosendaal; R Jude Samulski; Steven M Soltys; Richard Surosky; Liliane Tenenbaum; Darby L Thomas; Bart van Montfort; Gabor Veres; J Fraser Wright; Yili Xu; Olga Zelenaia; Lorena Zentilin; Richard O Snyder
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

4.  Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material.

Authors:  Eduard Ayuso; Véronique Blouin; Martin Lock; Susan McGorray; Xavier Leon; Mauricio R Alvira; Alberto Auricchio; Stephanie Bucher; Abdelwahed Chtarto; K Reed Clark; Christophe Darmon; Monica Doria; Will Fountain; Guangping Gao; Kai Gao; Mauro Giacca; Juergen Kleinschmidt; Barbara Leuchs; Catherine Melas; Hiroaki Mizukami; Marcus Müller; Yvet Noordman; Olivier Bockstael; Keiya Ozawa; Catherine Pythoud; Marina Sumaroka; Richard Surosky; Liliane Tenenbaum; Inge van der Linden; Brigitte Weins; J Fraser Wright; Xinhua Zhang; Lorena Zentilin; Fatima Bosch; Richard O Snyder; Philippe Moullier
Journal:  Hum Gene Ther       Date:  2014-11       Impact factor: 5.695

5.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

6.  Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.

Authors:  Giou-Teng Yiang; Horng-Jyh Harn; Yung-Luen Yu; Sheng-Chuan Hu; Yu-Ting Hung; Chia-Jung Hsieh; Shinn-Zong Lin; Chyou-Wei Wei
Journal:  J Biomed Sci       Date:  2009-05-07       Impact factor: 8.410

7.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

Review 8.  Transient transfection methods for clinical adeno-associated viral vector production.

Authors:  J Fraser Wright
Journal:  Hum Gene Ther       Date:  2009-07       Impact factor: 5.695

9.  Immobilized cobalt affinity chromatography provides a novel, efficient method for herpes simplex virus type 1 gene vector purification.

Authors:  Canping Jiang; James B Wechuck; William F Goins; David M Krisky; Darren Wolfe; Mohammad M Ataai; Joseph C Glorioso
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.

Authors:  William W Hauswirth; Tomas S Aleman; Shalesh Kaushal; Artur V Cideciyan; Sharon B Schwartz; Lili Wang; Thomas J Conlon; Sanford L Boye; Terence R Flotte; Barry J Byrne; Samuel G Jacobson
Journal:  Hum Gene Ther       Date:  2008-10       Impact factor: 5.695
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.